production, quality control and biological evaluation of 153sm-tthmp as a possible bone palliation agent

Authors

zohreh naseri

amir reza jalilian

ali nemati kharat

ali bahrami-samani

mohammad ghannadi-maragheh

abstract

introduction: various bone palliative therapeutic agents have been developed and widely used for bone metastasis such as 153sm-edtmp. in this study, production, quality control and biodistribution studies of a newly developed therapeutic compound have been presented followed by imaging studies in wild-type rodents. methods: 153sm-tthmp was prepared starting from 153sm-smcl3, prepared by neutron activation of an enriched 152sm sample (purity >98%), and in-house synthesized tthmp in 1h at 25°c followed by stability tests, partition coefficient determination and biodistribution studies of in wild-type rodents using scarification and spect imaging. results: the radiolabled sm complex was prepared in high radiochemical purity (>99%, itlc) and specific activity of 278 gbq/mmol and demonstrated significant stability at 4, 25 and 37°c (in presence of human serum). initial biodistribution data showed significant bone accumulation of the tracer in 48h. conclusion: 153sm-tthmp can be a potential candidate for bone pain palliation therapy in skeletal metastases, although further biological studies in other mammals is still needed.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Production, quality control and biological evaluation of 153Sm-TTHMP as a possible bone palliation agent

Introduction: Various bone palliative therapeutic agents have been developed and widely used for bone metastasis such as 153Sm-EDTMP. In this study, production, quality control and biodistribution studies of a newly developed therapeutic compound have been presented followed by imaging studies in wild-type rodents. Methods: 153Sm-TTHMP was prepared starting from 153<...

full text

Production, Quality Control and Biological Evaluation of 166Ho-PDTMP as a Possible Bone Palliation Agent

Objective(s):In this study, 166Ho-1,2-propylene di-amino tetra(methy1enephosphonicAcid) (166Ho-PDTMP) complex  was prepared as a bone palliation agent. Materials and Methods:The complex was successfully prepared using an in-house synthesized EDTMP ligand and 166HoCl3. Ho-166 chloride was obtained by thermal neutron irradiation (1 × 1013 n.cm-2.s-1) of natural Ho(NO3)3 samples  followed by radio...

full text

Production, quality control and biological evaluation of Sm-TTHMP as a possible bone palliation agent

Introduction: Various bone palliative therapeutic agents have been developed and widely used for bone metastasis such as Sm-EDTMP. In this study, production, quality control and biodistribution studies of a newly developed therapeutic compound have been presented followed by imaging studies in wild-type rodents. Methods: Sm-TTHMP was prepared starting from Sm-SmCl3, prepared by neutron activati...

full text

production, quality control and biological evaluation of 166ho-pdtmp as a possible bone palliation agent

objective(s):in this study, 166ho-1,2-propylene di-amino tetra(methy1enephosphonicacid) (166ho-pdtmp) complex  was prepared as a bone palliation agent. materials and methods:the complex was successfully prepared using an in-house synthesized edtmp ligand and 166hocl3. ho-166 chloride was obtained by thermal neutron irradiation (1 × 1013 n.cm-2.s-1) of natural ho(no3)3 samples  followed by radio...

full text

Production, biodistribution assessment and dosimetric evaluation of 177Lu-TTHMP as a bone pain palliation agent

Objective(s): Recently, bone-avid radiopharmaceuticals have been shown to have potential benefits for the treatment of widespread bone metastases. Although 177Lutriethylene tetramine hexa methylene phosphonic acid (abbreviated as 177Lu- TTHMP), as an agent for bone pain palliation, has been evaluated in previous studies, there are large discrepancies between the obtained results. In this study,...

full text

Production, Quality Control and Biological Evaluation of 166Ho-PDTMP as a Possible Bone Palliation Agent

OBJECTIVE(S) In this study, (166)Ho-1,2-propylene di-amino tetra(methy1enephosphonicAcid) ((166)Ho-PDTMP) complex was prepared as a bone palliation agent. MATERIALS AND METHODS The complex was successfully prepared using an in-house synthesized EDTMP ligand and (166)HoCl3. Ho-166 chloride was obtained by thermal neutron irradiation (1 × 1013 n.cm-2.s-1) of natural Ho(NO3)3 samples followed by...

full text

My Resources

Save resource for easier access later


Journal title:
iranian journal of nuclear medicine

Publisher: tehran university of medical sciences

ISSN 1681-2824

volume 19

issue 2 2012

Keywords
[ ' s m ' , 1 5 3 , ' t t h m p ' , ' r a d i o p h a r m a c e u t i c a l ' , ' t h e r a p y ' , ' b i o d i s t r i b u t i o n ' , ' i m a g i n g ' ]

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023